Project Grant R15ES033393
- This $418,702 federal Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) will support research at Baylor University to investigate the impact of altered biotransformation pathways on the ability of Gulf killifish to adapt to legacy pollutants like polychlorinated biphenyls (PCBs) and polycyclic aromatic hydrocarbons (PAHs). The project will examine how a deletion in the aryl hydrocarbon receptor (AhR)...
- This Project Grant award of $168,316, funded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113), supports research conducted by Harvard T.H. Chan School of Public Health beginning May 19, 2025 and concluding February 29, 2028. The research investigates the biological mechanisms underlying children's heightened vulnerability to lead-induced neurotoxicity, specifically examining the role of apoptosis (programmed cell death)...
- Federal Project Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $246,562 under the Environmental Health program (CFDA 93.113) effective May 1, 2025, with a completion date of December 31, 2027. This research initiative investigates the impacts of perinatal metal mixture exposure and prenatal maternal stress on neural and cognitive development underlying adolescent risk-taking behaviors....
- Federal Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded The Washington University a $1,575,500 Project Grant effective September 26, 2025, through June 30, 2030, under the Environmental Health program (CFDA 93.113). This research initiative investigates the relationship between prenatal chemical exposures—specifically polybrominated diphenyl ethers (PBDEs) and organophosphate esters (OPEs), which are flame retardant chemicals—and depression risk in...
- This Project Grant award for $448,383 from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) federal grant program will fund research to determine the impact of maternal ingestion of cyanotoxins on the development and function of the stress axis in offspring. The primary objectives are to: 1) Determine if sub-chronic maternal exposure to the cyanotoxin microcystin-LR disrupts the development of brain regions that control the stress...
- This Project Grant award, provided by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) Federal Grant Program, aims to investigate the impact of exposure to organophosphate flame retardants (OPFRs) on metabolic and brain aging. The total funding amount is $409,508, with the award period running from September 16, 2024 to August 31, 2026. The key products and services to be delivered under this grant include: Defining the extent to...
- Federal Grant Award Summary Boston University Medical Campus received a $147,486 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113), effective November 1, 2025 through August 31, 2028. This research initiative examines the neurodevelopmental impacts of early-life exposure to ferroalloy metal mixtures—specifically manganese, lead, chromium, and copper—on adolescent cognitive outcomes. The project...
- Federal Project Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded $498,000 through the Environmental Health program (CFDA 93.113) to Icahn School of Medicine at Mount Sinai on August 25, 2025, for a three-year project extending through July 31, 2028. This R00 Career Transition Award supports research investigating how prenatal exposure to fine particulate air pollution (PM2.5) influences neurodevelopmental outcomes in children. The investigator will...
- Federal Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded The Pennsylvania State University a $249,000 Project Grant under the Environmental Health program (CFDA 93.113) on August 12, 2025, to investigate the interaction of perinatal organophosphate flame retardant (OPFR) exposure and adult chronic stress on cognitive processing. The research will examine how early-life exposure to endocrine-disrupting compounds (EDCs)—specifically OPFRs acting on...
- This Project Grant, awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health federal grant program (CFDA 93.113), will support research investigating the impact of phthalate and bisphenol exposure on infant reproductive development during the critical "minipuberty" period in the first 6 months of life. The $719,892 award, provided to New York University, will fund a study nested within the NYU Children's Health and Environment Study (NYU...
PCB-INDUCED PRIMING OF MICROGLIAL ACTIVITY ACROSS SEXES AND DEVELOPMENT - PROJECT SUMMARY / ABSTRACT POLYCHLORINATED BIPHENYLS (PCBS) REMAIN UBIQUITOUS ENVIRONMENTAL CONTAMINANTS AND EXPOSURE TO THEM IS ASSOCIATED WITH INCREASED RISK OF NEURODEVELOPMENTAL AND MOOD DISORDERS. THESE DISORDERS TEND TO OCCUR MORE FREQUENTLY IN INFANT MALE AND ADOLESCENT FEMALE INDIVIDUALS, AND ARE ASSOCIATED WITH ALTERED FUNCTION OF MICROGLIA, THE RESIDENT IMMUNE CELLS OF THE BRAIN. WHILE SIGNIFICANT GAINS HAVE BEEN MADE IN UNDERSTANDING EFFECTS OF PCBS ON NEURONS, DIRECT EFFECTS OF PCBS AND MOST OTHER ENVIRONMENTAL TOXICANTS ON MICROGLIA ARE UNKNOWN. THE OVERALL OBJECTIVE OF THIS PROPOSAL IS TO IDENTIFY DIRECT EFFECTS AND PUTATIVE MECHANISMS OF PCB ACTION ON MICROGLIAL FUNCTION AND POSSIBLE NEURONAL CONSEQUENCES. THE CENTRAL HYPOTHESIS IS THAT PCBS WILL PRIME MICROGLIA TO PRODUCE EXAGGERATED RESPONSES TO A SECONDARY CHALLENGE IN AGE- AND SEX-SPECIFIC WAYS. THE APPLICATION PROPOSES TO USE MICROGLIA ACUTELY ISOLATED FROM MALE AND FEMALE NEONATAL AND ADOLESCENT WHOLE BRAINS AND TREATED TO INDIVIDUAL PCB CONGENERS, AN ENVIRONMENTALLY REPRESENTATIVE MIXTURE, OR VEHICLE IN VITRO PRIOR TO A CONTROL OR IMMUNE CHALLENGE. AIM 1 IS TO EVALUATE THE EFFECTS OF PCB EXPOSURE ON MICROGLIAL CYTOKINE SIGNALING AND REGULATION. IL1B AND TNFA EXPRESSION AND RELEASE WILL BE ASSAYED WITH QPCR AND ELISA. EXPRESSION AND LOCALIZATION OF PRO-INFLAMMATORY TLR4 RECEPTOR AND NFKB TRANSCRIPTION FACTOR REQUIRED FOR CYTOKINE EXPRESSION WILL ALSO BE DETERMINED WITH IMMUNOCYTOCHEMISTRY. AIM 2 IS TO INTERROGATE EFFECTS AND PUTATIVE MECHANISMS OF PCBS ON MICROGLIAL OXIDATIVE STRESS. PRODUCTION OF ROS/RNS AND PEROXYNITRITE- ASSOCIATED CELL DAMAGE IN MIXED CELL CULTURES, AND EXPRESSION OF PCB-SENSITIVE RECEPTORS THAT MODULATE CALCIUM AND ROS/RNS PRODUCTION IN MICROGLIA, WILL BE DETERMINED. AIM 3 IS TO IDENTIFY EFFECTS AND PUTATIVE MECHANISMS OF PCBS ON MICROGLIAL PHAGOCYTOSIS. MICROGLIAL PHAGOCYTOSIS OF FLUORESCENTLY LABELED LATEX BEADS AND EXPRESSION OF PHAGOCYTOSIS-RELATED GENES WILL BE DETERMINED BY FLOW CYTOMETRY AND QPCR. MICROGLIA MORPHOLOGY ASSOCIATED WITH PHAGOCYTOSIS WILL BE DETERMINE IN MIXED CELL CULTURES BY IMMUNOHISTOCHEMISTRY. THE PROPOSED WORK IS INNOVATIVE IN THAT IT IS THE FIRST TO DIRECTLY STUDY SEX DIFFERENCES IN MICROGLIAL RESPONSES TO ENVIRONMENTAL TOXICANTS AND USE ACUTE ISOLATION TECHNIQUES TO BETTER MAINTAIN IN VIVO PHENOTYPES. THESE STUDIES ARE EXPECTED TO CONTRIBUTE TO A CONCEPTUAL FRAMEWORK FOR IDENTIFYING MECHANISTIC TARGETS OF PCB ACTION IN MICROGLIA. THIS KNOWLEDGE COULD PROVIDE A STRONG FOUNDATION FOR THE PURSUIT OF MICROGLIA-DIRECTED THERAPEUTIC STRATEGIES AIMED AT TREATING OR PREVENTING TOXICANT-INDUCED NEURODEVELOPMENTAL DISORDERS. THIS INFORMATION COULD ALSO INFORM POPULATION-TARGETED EXPOSURE MITIGATION STRATEGIES. AS AN AREA-R15 APPLICATION, THESE STUDIES WILL ENGAGE STUDENTS IN INDEPENDENT AND MERITORIOUS RESEARCH, STRENGTHENING THE INSTITUTIONAL RESEARCH ENVIRONMENT AT AN INSTITUTION SERVING A LARGE NUMBER OF STUDENTS UNDERREPRESENTED IN SCIENCE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/7/25 | ||
| Not listed | $446.9k | 7/29/22 | ||
| Not listed | $446.9k | 7/29/22 |